vesnarinone and Benign Neoplasms studies

vesnarinone and Benign Neoplasms

vesnarinone has been researched along with Benign Neoplasms in 3 studies

Research Excerpts

Excerpt	Relevance	Reference
"To evaluate the maximum-tolerated dose, dose-limiting toxicities (DLTs), and pharmacokinetic profile of vesnarinone given once daily in combination with gemcitabine."	2.69	Phase I and pharmacokinetic study of the differentiating agent vesnarinone in combination with gemcitabine in patients with advanced cancer. ( Drengler, RL; Eckhardt, SG; Felton, SA; Garner, AM; Hammond, LA; Hidalgo, M; Mallikaarjun, S; Patnaik, A; Rowinsky, EK; Siu, LL; Tammara, BK; Von Hoff, DD, 2000)
"Vesnarinone has been shown to be a unique anti-proliferating, differentiation-inducing and apoptosis inducing drug against several human malignancies, including leukemia and several solid tumors."	2.42	Vesnarinone: a differentiation-inducing anti-cancer drug. ( Fujimori, T; Hino, S; Kawamata, H; Nakashiro, K; Omotehara, F; Uchida, D, 2003)

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	3 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Timeframe

Studies, this research(%)

All Research%

pre-1990

0 (0.00)

18.7374

1990's

0 (0.00)

18.2507

2000's

3 (100.00)

29.6817

2010's

0 (0.00)

24.3611

2020's

0 (0.00)

2.80

Authors

Authors	Studies
Kawamata, H	2
Omotehara, F	1
Nakashiro, K	1
Uchida, D	1
Hino, S	1
Fujimori, T	2
Tachibana, M	1
Imai, Y	1
Patnaik, A	1
Rowinsky, EK	1
Tammara, BK	1
Hidalgo, M	1
Drengler, RL	1
Garner, AM	1
Siu, LL	1
Hammond, LA	1
Felton, SA	1
Mallikaarjun, S	1
Von Hoff, DD	1
Eckhardt, SG	1

Studies

Kawamata, H

Omotehara, F

Nakashiro, K

Uchida, D

Hino, S

Fujimori, T

Tachibana, M

Imai, Y

Patnaik, A

Rowinsky, EK

Tammara, BK

Hidalgo, M

Drengler, RL

Garner, AM

Siu, LL

Hammond, LA

Felton, SA

Mallikaarjun, S

Von Hoff, DD

Eckhardt, SG

Reviews

2 reviews available for vesnarinone and Benign Neoplasms

Article	Year
Vesnarinone: a differentiation-inducing anti-cancer drug. Anti-cancer drugs, 2003, Volume: 14, Issue:6 Topics: Animals; Antineoplastic Agents; Apoptosis; Humans; Mice; Neoplasms; Pyrazines; Quinolines; Repressor	2003
Differentiation-inducing therapy for solid tumors. Current pharmaceutical design, 2006, Volume: 12, Issue:3 Topics: Animals; Antineoplastic Agents; Cell Differentiation; Humans; Neoplasms; PPAR gamma; Pyrazines; Quin	2006

Article

Year

Vesnarinone: a differentiation-inducing anti-cancer drug.

Anti-cancer drugs, 2003, Volume: 14, Issue:6

Topics: Animals; Antineoplastic Agents; Apoptosis; Humans; Mice; Neoplasms; Pyrazines; Quinolines; Repressor

2003

Differentiation-inducing therapy for solid tumors.

Current pharmaceutical design, 2006, Volume: 12, Issue:3

Topics: Animals; Antineoplastic Agents; Cell Differentiation; Humans; Neoplasms; PPAR gamma; Pyrazines; Quin

2006

Trials

1 trial available for vesnarinone and Benign Neoplasms

Article	Year
Phase I and pharmacokinetic study of the differentiating agent vesnarinone in combination with gemcitabine in patients with advanced cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Dec-01, Volume: 18, Issue:23 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Differentiation; Deoxyc	2000

Article

Year

Phase I and pharmacokinetic study of the differentiating agent vesnarinone in combination with gemcitabine in patients with advanced cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Dec-01, Volume: 18, Issue:23

Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Differentiation; Deoxyc

2000